Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2016

View Archived Issues

Novartis offers overview of first quarter 2016

First-in-human results show potential of Ad26.ZEBOV and MVA-BN Filo Ebola vaccines

Lipoic acid shown to reduce brain atrophy and exert clinical benefit in MS

ARN-6039: a promising treatment for neuroinflammatory demyelinating disease

Some improvements seen with calpain inhibitor ALA-1.0 in a rat model of traumatic brain injury

eFFECTOR Therapeutics describes activity of anticancer Mnk1/2 inhibitor eFT-508

Midatech Pharma reports preclinical pharmacokinetic data with Q-Octreotide

AnGes and VIDO-InterVac collaborate to develop Ebola polyclonal antibody therapy

FDA grants fast track designation for recAP in acute kidney injury

hVIVO and SEEK in joint venture investment to develop vaccines against influenza and flu

Positive preliminary data presented from the Tanzanite phase II trial

Acerta Pharma patents BTK inhibitors

Takeda Pharmaceutical announces TBK1 inhibitors

TGF-beta receptor inhibitors described in recent Lilly patent

Merck KGaA divulges BTK inhibtors

First patient dosed in Exicure's phase I study of AST-005

Prometic Life Sciences provides new data from phase II trial of PBI-4050

Bayer Schering Pharma presents CDK inhibitors

FDA grants breakthrough therapy designations to Ilaris for rare types of periodic fever syndromes

Ironwood Pharmaceuticals gains exclusive U.S. rights to lesinurad

FDA grants orphan drug designation to Fibrocell Science's FCX-013

Zymeworks and GSK enter second bispecific antibody agreement

FDA outlines requirements for Catalyst's planned Firdapse NDA resubmission

Queensland Health and University of Queensland collaborate on Zika virus detection test

Queen's University Belfast and Domainex receive award to advance NSCLC treatments

Sun Pharma and partners establish malaria elimination demonstration project

Ariad initiates phase I/II trial of oral AP-32788 in NSCLC

FDA clears phase II trial of ezutromid in DMD to open in U.S.

FDA issues complete response letter for digital medicine